XTRA:BAYNPharmaceuticals
Bayer (XTRA:BAYN): Assessing Valuation After Fresh Pipeline Progress and Regulatory Milestones
Bayer (XTRA:BAYN) has packed several clinical and regulatory milestones into just a few days, and the stock is now trading in the context of a much busier innovation story than markets saw earlier this year.
See our latest analysis for Bayer.
That flurry of trial starts and regulatory filings seems to be resonating with investors, with Bayer’s 1 month share price return of 32.45% feeding into an 87.38% year to date share price gain, even though the 3 year total shareholder return of negative...